Even with a lipid content of over 10% in the human body, lipids were not in the central scientific focus during the last decade. However, more and more evidence is provided that non-genetically determined biomolecules such as metabolites and lipids are the key to biomolecular regulation. Today it is obvious that lipids are not only important for energy homeostasis and as an environmental-cellular barrier, but also represent a central part of our signal transduction machinery. Disruptions of the sensitive lipid metabolism are highly correlated with different types of diseases including thrombocytopenia, metabolic syndrome, diabetes, obesity and hyperlipidemia. This is especially true for the latter ones, which are also reaching pandemic levels, causing a larger annual health burden than infectious diseases. Therefore, lipid metabolism is again becoming an emerging scientific field and is a central part of pharmacological research today (statins, cyclooxygenase inhibitors, endurobol in doping). Thus, the mission of the Lipidomics group at ISAS is to understand the lipids in context with their proteins (enzymes) and building blocks (metabolites) in a true systems biology way.